Candel Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (ticker: CADL) is a clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. Headquartered in Needham, Massachusetts, the company develops multimodal biological immunotherapies designed to improve outcomes for cancer patients. Its business model is centered on research and development rather than commercialization, and it currently has no marketed products. As a result, Candel fits the profile of a high-risk, high-upside oncology biotech whose valuation is driven primarily by clinical data, regulatory milestones, and financing execution. Founded in June 2003 under the laws of Delaware, Candel has evolved into a platform company focused on viral and biological immunotherapy. Its scientific approach is built around oncolytic viral technologies intended to trigger in situ immunization against tumor-specific antigens and neoantigens after tumor cell lysis. The company’s two principal clinical candidates are CAN-2409, also known as aglatimagene besadenovec, and CAN-3110, also known as linoserpaturev. CAN-2409 is Candel’s most advanced asset and is being evaluated in localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC). CAN-3110 is being developed primarily for recurrent glioblastoma, extending the platform into a particularly challenging solid-tumor setting. From a competitive standpoint, Candel operates in a specialized segment of oncology that sits between oncolytic virotherapy, gene therapy, and precision immuno-oncology. Its differentiation lies in a proprietary platform and a relatively broad clinical pipeline for a company of its size. However, it competes with larger biotechnology and pharmaceutical companies that have deeper resources, broader commercial infrastructure, and stronger balance sheets. For investors, this means the investment case remains highly binary: success will depend on clinical efficacy, tolerability, and eventual regulatory success. Recent corporate developments have been material. In 2026, Candel reported continued progress across its pipeline, including encouraging interim data for CAN-3110 in recurrent glioblastoma. The company also said it raised approximately $100 million in an equity offering in February 2026 and later entered into a $100 million royalty funding agreement with RTW to help support a potential launch of aglatimagene besadenovec in localized prostate cancer. Management has also stated that successful phase 2a studies were completed in NSCLC and PDAC, while corporate priorities have shifted toward prostate cancer and NSCLC development. For investors following the NYSE/NASDAQ U.S. healthcare universe, CADL remains a development-stage oncology story with meaningful event-driven catalysts and significant execution risk.